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The 2019 Havemeyer Workshop brought together researchers and clinicians to discuss
the latest information on Equine Asthma and provide future research directions. Current
clinical andmolecular asthma phenotypes and endotypes in humans were discussed and
compared to asthma phenotypes in horses. The role of infectious and non-infectious
causes of equine asthma, genetic factors and proposed disease pathophysiology
were reviewed. Diagnostic limitations were evident by the limited number of tests and
biomarkers available to field practitioners. The participants emphasized the need for
more accessible, standardized diagnostics that would help identify specific phenotypes
and endotypes in order to create more targeted treatments or management strategies.
One important outcome of the workshop was the creation of the Equine Asthma Group
that will facilitate communication between veterinary practice and research communities
through published and easily accessible guidelines and foster research collaboration.
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INTRODUCTION
The effort to clarify the phenotype and terminology used to characterize horses with chronic
inflammatory airway disease started in 2000 with a workshop in East Lansing, Michigan (1).
Several workshops were subsequently held with similar goals in mind with the latest hosted in
Cabourg, France in 2014 (2). In the last few years, the terminology has further evolved with the
term equine asthma (EA) now being recommended to describe horses with chronic respiratory
signs ranging in severity from mild to severe that were previously referred as inflammatory airway
disease and recurrent airway obstruction, respectively (3). Although strong evidence supports the
role of exposure to environmental dust in the pathophysiology of both mild and severe EA, the
potential role of infectious agents (bacterial and viral) has not been clearly established.
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The goal of the 2019HavemeyerWorkshop on Equine Asthma
was to bring together researchers and clinicians from different
disciplines who are actively investigating airway inflammation to
discuss the latest information on this topic and provide some
comparative perspective from human asthma. The workshop
was designed to facilitate productive discussions that would
inform potential future revisions of the 2016 American College
of Veterinary Internal Medicine (ACVIM) Consensus Statement
on mild-moderate EA (3) and provide future research directions.
The present report follows the format of the workshop. The
manuscript is organized thematically starting with the recent
advancements in the understanding of the classification and
diagnosis of human and equine asthma. The second part is
centered on the etiology and pathophysiology of EA. The third
and final section of the manuscript summarizes the extensive
discussions conducted during the workshop with the goal of




Clinical asthma phenotypes have been recognized for many
decades but were collapsed into a unified hypothesis of asthma
as an allergic disease in 1989 when age adjusted levels of
immunoglobulin E were associated with asthma. It has taken
more than 20 years to consider the heterogeneity of asthma again
with an emerging emphasis on endotypes, an intrinsically more
interesting approach to understanding asthma pathobiology
(4). The term “endotype” is used to describe a subtype of
disease defined by a molecular mechanism, genetic variation
or by treatment response (5, 6). Cluster analyses of asthma
cohorts have revealed groups with different ages of onset, lung
function, concordance or lack thereof between measures of
airway inflammation by sputum analysis and symptoms. A recent
review of asthma by a panel of experts has focused on the need
to recognize asthma in its diverse forms and to identify treatable
traits. This extensive review has highlighted areas for future
attention (7).
The application of the analysis of gene expression to airway
epithelial cells and sputum cells from well-characterized groups
of asthmatics has led to the appreciation of asthma associated
with T helper 2 cytokines and non-T2 asthma (8). The former
is the more allergic subset with higher IgE and peripheral and
sputum eosinophilia. Non-T2 asthma has fewer of these features
and is less responsive to inhaled corticosteroids. T cells that
express interleukin-17 have been linked to severe neutrophilic
asthma. These so-called Th17 cells have been shown in animal
models to be associated with steroid-unresponsiveness. The Th1
cytokine interferon-γ likewise has been found to be expressed in
the airways of severe asthmatics.
In recent years there has emerged another lymphoid cell
that participates in host responses to mucosal injury. These
innate lymphoid cells are lineage negative, lacking the usual
lymphocyte surface markers (9). They express similar panels
of cytokines to the T helper subsets and are labeled innate
lymphoid cell (ILC) 1, 2, and 3. They are rapidly activated
by epithelial signals such as thymic stromal lymphopoietin
(TSLP), interleukins 25 and 33, molecules termed alarmins. The
secretion of IL-5 and IL-13 by ILC2 may lead to a pattern of
inflammation previously interpreted as Th2. Innate lymphoid
cells are less steroid sensitive. Additionally, alarmins prime cells
such as dendritic cells and therefore may have a role in adaptive
immunity as well as innate immune responses. The synthesis
of amphiregulin, an epidermal growth factor receptor ligand,
by ILC2s but also Th2 cells, is postulated to promote mucosal
integrity. One could anticipate that viral infection of epithelial
cells or damage by irritants giving rise to inflammation mediated
by ILCs. However, their roles have yet to be fully explored.
Transcriptomic analysis of sputum has revealed three patterns
of inflammation and gene signatures consistent with both Th2
and ILC2 driven inflammation and oxidative stress (10). The
descriptions of molecular mechanisms of inflammation may
still be considered as a deeper form of phenotyping. However,
the application of novel biologics to treat asthma is now
implicating certain pathways in disease and therefore is providing
us with true disease endotypes. Most of the progress in the
identification of treatable traits has related to the T2 phenotype.
Biologics targeting IgE (omalizumab), IL-5 and therefore, the
eosinophil (mepolizumab, benrazilumab, rezlizumab) and the
T2 cytokines (dupilumab) have all demonstrated efficacy in
reducing exacerbations of asthma. Recent results of studies
targeting the alarmin TSLP and therefore both T2 high and low
asthma have confirmed efficacy against acute attacks of asthma.
Oxidative stress in asthma has not been specifically addressed.
A problematic form of asthma is that associated with airway
remodeling and fixed airway obstruction. The association with
mucus plugging and eosinophilic inflammation has been recently
identified as a potential factor in long term impaired airway
function (11).
Severe equine asthma is typically a neutrophilic form of
asthma although expression of T2 cytokines has been described
(12). There is also evidence that IL-17 is expressed in equine
asthma and its effects on neutrophil survival are steroid-
insensitive (13, 14). Although neutrophilic human asthma is less
steroid-sensitive than the eosinophilic phenotype, severe equine
asthma is responsive to steroid treatment despite the presence
of neutrophilic inflammation. Severe equine asthma shares the
structural remodeling of the airways with human asthma and a
part of the remodeling change is reversible with steroid treatment
as well as withdrawal from the inciting stimulus (15). Studies
of airway remodeling in human asthma with treatment have
not addressed key components of remodeling such as increased
airway smooth muscle mass.
CLINICAL PHENOTYPES OF EQUINE
ASTHMA—JEAN-PIERRE LAVOIE
The purpose of the 2007 ACVIM Consensus Statement on mild-
moderate EA was to review the current knowledge and opinions
concerning this condition and to help practitioners differentiate
mild-moderate EA from severe EA (16). The consensus was
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revised in 2016 and discussed the use of EA to describe these
conditions (3). The revised consensus recognized that asthmatic
horses of all severities have common clinical presentations (such
as chronic cough, excess mucus, poor performance) but also a
wide heterogeneity in terms of triggering factors, severity, and
pathologic characteristics.
A phenotype is the observable physical properties of an
organism, including measurable laboratory findings, which
is the result of the expression of the genes in response
to the environment (17). Identifying distinct phenotypes is
of interest if they facilitate the diagnosis, the prognosis or
allow the implementation of targeted therapy. While currently
loosely defined, the EA phenotypes discussed in the 2016
Consensus statements were based on clinical presentation (severe
vs. mild/moderate), triggering factors (barn/hay or pasture),
endoscopy findings (mucus) and bronchoalveolar cytology.
From a clinical standpoint, further dividing EA as distinct
“mild” and “moderate” phenotypes may promote recognition
that asthma is an underdiagnosed cause of exercise intolerance
in high performance horses. Horses with a cough or increased
respiratory rate at rest or following exercise will commonly
undergo further diagnostic procedures to confirm asthma, or
“anti-asthma” treatments will be implemented. However, this is
generally not the case when no clinical signs suggestive of an
airway disease are present. The term “mild EA” could describe
the condition affecting these horses, while “moderate EA” would
be used when clinical signs of airway disease (such as cough) are
present, but without the periods of labored breathing at rest seen
in “severe EA” (18). The inflammatory airway cell phenotypes
(neutrophils, mast cells, eosinophils) were recognized in the
2007 and 2016 consensus statements (3, 16). Future phenotypes
may include the age (early or late) of appearance of clinical
signs, or specific remodeling features affecting the airways, if
these new features are shown to facilitate prognostication or the
implementation of specific therapy.
The future development of new portable and sensitive devices
for measuring the lung function of horses (forced oscillation
or flow interruption techniques), or the discovery of blood
biomarkers for EA would help not only to facilitate the diagnosis
of mild and moderate forms of EA in clinical practice, but also to
possibly identify new phenotypes for these conditions.
To date, different inflammatory pathways have been proposed
as contributing to EA, which may eventually lead to novel
therapies (19). The discrepancies between results of the different
studies may be an indication of different endotypes in EA,
although future studies on large cohorts of horses from
multiple sites would be required before specific endotypes
can be recognized. Multicenter tissue banking could facilitate
these studies.
In summary, the 2016 ACVIM Consensus Statement
recognized the currently known distinctive features of
EA. Further defining “mild” and “moderate” EA based
on the presence or absence of easily identified clinical
signs may promote the investigation of the subclinical
(mild) phenotype. The identification of novel phenotypes
and endotypes may lead to “precision medicine” where
treatments most likely to help equine patients would be
selected. This approach is now implemented in humans
and may eventually be applicable to horses if supported by
scientific research.
SUMMER PASTURE-ASSOCIATED SEVERE
EQUINE ASTHMA: PHENOTYPE AND
TRIGGERS—CYPRIANNA SWIDERSKI
Severe equine pasture asthma (EPA) is characterized by episodes
of reversible airway obstruction in horses grazing pasture
during the summer in hot humid climates (20). Affected horses
demonstrate neutrophilic airway inflammation, airway hyper-
responsiveness extending throughout the season of remission,
and airway remodeling (21, 22). The author’s experience is
restricted to EPA as first described in horses residing in Louisiana,
and diagnosed in states with subtropical climates (Mississippi,
Alabama, and Florida) (20). Veterinarians in regions of adjoining
states and distant states (Oregon) describe similar signs in horses
grazing pastures during hot humid conditions. EPA is described
in the United Kingdom where it differs in its association with
hot dry weather or exposure to dust from harvest/burning
of crops (23). EPA demonstrates adult onset (12 ± 6 years;
range 1–29 years) without sex predilection (24). Asthma
exacerbations generally begin in summer (July), persisting until
temperature and humidity decrease (October/November) (25).
Fewer horses experience asthma in the spring. A history of prior
seasonal cough and/or exercise intolerance may be identified.
Improvement within hours to days of isolation from pasture
particulates in a stall environment is a key diagnostic feature
of EPA in the southeastern USA (20); some severe cases
necessitate isolation in a climate climate-controlled environment.
In the author’s experience, without adequate environmental
management, disease severity is progressive and responsiveness
to parenteral corticosteroids decreases.
Though specific agent(s) that elicit EPA exacerbation are
not identified, the response to stall housing implicates seasonal
pasture-associated particulates. Costa et al. reported increases
in grass but not tree pollens were significantly associated with
EPA exacerbation using a pollen station ∼90 miles from affected
horses (25). In this regard, intact pollen is too large to reach
the respirable zone of humans in order to elicit asthma, but
moist conditions that are associated with EPA exacerbations can
shatter pollen and disseminate respirable particles (26). Grass
pollen sensitization is classically associated with Th2 responses,
IgE-mediated hypersensitivity, and eosinophilic inflammatory
infiltrates. However, chronic exposure to Th2 sensitizing
antigens and to complex antigen combinations that include Th2
sensitizing antigens each generate Th17 responses accompanied
by neutrophilic airway inflammation that typifies EPA (27, 28).
Subtopical grasses differ substantially from grasses in
temperate and continental climates (29). Pollen from subtropical
grass subfamilies is important to rhinitis and human asthma in
subtropical zones of Australia, Asia, India, Africa, and America.
Pollination seasons for Bahia and Bermuda grass (spring through
September/October) align to the season of EPA exacerbation
(30, 31). The pollen season for Johnson grass is temperature
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dependent, flowering fromMay to July, with higher temperatures
moving flowering later into Autumm (32).
A role for fungal triggering in EPA exacerbation is suggested
by the near identical clinical picture presented by horses with EPA
and barn dust-associated severe asthma, wherein a role for fungal
triggering is substantiated in the latter (33). Chronic neutrophilic
airway inflammation characterizing both forms of severe equine
asthma also aligns to Th17-mediated neutrophilic inflammation
in fungal asthma models (34). Of the more than 100 species of
fungi that exist in biotropic relationships with Bermuda, Bahia,
and Johnson grasses, Curvularia, Helminthosporium, Alternaria,
Puccinia, Epicoccum, and Fusarium are implicated in eliciting
human asthma (35). Costa et al. identified fungal spores of
the genus Nigrospora, and Curvularia, as well as basidiospores,
as temporally associated with exacerbations of pasture asthma
(25). These findings are in agreement with reported correlations
between EPA exacerbation and high dew point temperature (25).
Specifically, Nigrospora conidia and basidiospore release increase
with increasing relative humidity, resulting in a peak in spore
counts during the early morning and aligning to the association
of EPA exacerbations with increased dew point temperature (25,
36). In contrast, conidia of Cladosporium, Alternaria, Epicoccum,
and Dreschlera spp. are released during warm, dry, windy
conditions, while precipitation is required for release of many
ascospores. In this way, humidity influences fungi of relevance
to asthma in different locales which could influence associations
of pasture asthma in the UK with hot dry conditions, rather
than hot humid conditions precipitating pasture asthma in the
southeastern US.
As a chronic and progressive disease of undetermined
etiology, EPA is most effectively managed by segregation from
inciting grass pastures during warm seasons. The necessity
to segregate horses from pasture, particularly at a time when
they are typically extensively ridden and grazed, presents a
conundrum that is ultimately detrimental for most affected
horses. Accordingly, there is a critical need to identify the agents
that trigger EPA in order to improve disease management.
RECOMMENDED MINIMUM DATABASE
FOR DIAGNOSIS OF EQUINE ASTHMA BY
EQUINE PRACTITIONERS IN THE FIELD
VS. CRITERIA USED FOR
RESEARCH—MELISSA MAZAN
Both veterinary practitioners and researchers muse about the
diagnostic armamentarium available to physicians—if only we
had the chest CT, the advanced lung function testing, the
biomarkers—then we would be able to have a better diagnosis.
A quick search of the literature, however, shows us that our
counterparts face many of the same diagnostic dilemmas that
we do, albeit often with higher bills! While pulmonologists have
drawn upmultiple guidelines to help in the diagnosis of asthma in
humans with its multiple phenotypes and endotypes, physician-
diagnosed asthma criteria often fail to be consistent with the
official guidelines rendering the results of large epidemiologic
studies or clinical trials fraught with the perils of resting
findings on nebulous datasets. Various forms of spirometry
or simple pulmonary function testing are readily available in
human medicine, but few non-pulmonologists avail themselves
of objective data, and instead rest on reported symptoms such
as difficulty breathing on exertion, cough or positive response to
bronchodilation (37). Indeed, the GINA toolbox identifies “lack
of access to spirometry/bronchoprovocation tests” as a barrier
to implementation of GINA guidelines in human asthmatics
(38). Moreover, the heterogeneity in published algorithms for
diagnosis of asthma—more than 66 in the literature at last
count—make even an algorithm-based diagnosis unsure (39).
Thus, the conclusion that symptom-based diagnosis is associated
with a significant risk of over-diagnosis has been reached for
asthma in humans (40). The current push in human medicine to
refine both the phenotypes and endotypes for multiple different
subtypes of asthmas aims to elucidate the underlying causes and
thus treatments that may be very different. We are still searching
for the criteria that will help us with this in equine medicine.
If there are indeed mechanistically different groups of horses
within the categories of mild, moderate, and severe EA that
are associated with genetic differences or cellular or molecular
biomarkers, then perhaps we will gain better understanding of
treatment successes and failures and will be able more logically to
choose clinical therapies and predict responses.
The difficult case for the clinician and the researcher alike
is not the horse with severe EA—because the history and
clinical exam alone can often suffice to diagnose, and there is a
visible relief in respiratory embarrassment with administration
of bronchodilator (although it can take some time in horses
with diaphragmatic exhaustion) (41). The difficult horse is the
one with moderate/severe asthma in remission and the horse
with mild-moderate EA. As was recently pointed out, the biggest
difference that we note in the clinical diagnosis of horses
with mild-moderate EA vs. severe EA is the presence of an
increased respiratory effort at rest, which is due to the underlying
pathophysiology of bronchoconstriction, increased mucus, and
bronchiolar inflammation (42). The need, then, is to detect the
mildly or subclinically affected horse.
As veterinarians, we have at hand history, clinical signs,
lung function testing, radiographs, endoscopy, analysis of airway
secretions, blood biomarkers and clinical pathology which can
be used in a minimum database in order to classify horses into
clinically useful categories that have a pathophysiologic basis
that can simultaneously allow us to diagnose, treat, and translate
clinical cases into field research.
History
A tentative diagnosis of EA in its most severe form can often
be made on history alone, with the key component being the
recognition of episodes of reversible respiratory embarrassment
precipitated by exposure to specific triggers—namely, moldy
hay in the northeast of the United States, and pasture allergens
and particulates in the south. History in subclinical or mild
cases is seldom of such definitive use; this does not mean that
it is unimportant. Such questions as parentage (43), type of
feed and how it is fed (44), and heat and pollen counts at the
time of diagnosis (45) may be important risk factors for equine
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asthma. While it has been proposed that coughing and poor
performance may serve to define a phenotype of moderate vs.
mild EA (46), these signs are not sufficiently sensitive (47) and
would misclassify a subset of horses—they alert the clinician that
moderate EA is likely, but the absence of these signs does not rule
out disease. The connections between EA and viral or bacterial
disease are not linear, but it is becoming increasingly clear that
the connection exists (48, 49), thus a thorough history should
include probing for past infectious respiratory disease. One of
the best described questionnaire analysis tools for classification
of horses based on history is the HOARSI index (50), developed
as a means of distinguishing among normal, mild-moderate EA
or severe EA phenotypes. However, clinical signs and indices
are insufficiently sensitive to distinguish horses with mild-
moderate EA from normal horses or horses with severe EA in
remission (51).
Proposed minimum database for both practitioners in the field
and for research: A common history tool should be developed that
addresses the main concerns of parentage if known, current and
lifetime exposures to particulates and allergens including feeds and
feeding practices, barn environment, vaccinations, travel history,
and recent illnesses.
Clinical Scoring/Clinical Presentation
Multiple scoring systems have been shown to be useful for
distinguishing healthy horses from horses with severe EA
in exacerbation, but, similar to questionnaire indices, these
scoring systems do not help in the more difficult problem of
distinguishing horses with mild EA from healthy or severe EA in
remission (52). Indeed, 19 years ago, Robinson et al. found that
even in horses with historical severe EA, clinical score failed to
reflect low-grade airway obstruction, and suggested that without
easily used, field-accessible testing equipment, lower airway
disease would go underdiagnosed (53). Recently, the adapted
23-point scoring system has been shown to be the most useful
in discriminating mild from severe cases, but it is unlikely to
distinguish normal from subclinical disease (54), and the IDEASS
scoring system has recently been described as a useful scoring
system for moderate-to-severe equine asthma (55). Thus, while
clinical scoring is essential to a good examination and careful
research, and can potentially be useful in measuring response
to treatment in the individual, it is insufficient in making
the phenotypic distinction between mildly affected horses and
healthy horses.
Proposed minimum database for both practitioners in the field
and for research: The 23-point modified clinical score appears to
best stratify horses with obstruction ranging from mild to severe.
An application suitable for smart phone use would enhance the
adoption of a common scoring tool.
Lung Function Testing
In human asthma, the gold standard is the detection of variability
in pulmonary function using spirometry or other methods of
lung function testing (38). Unfortunately, lung function testing
remains available only to a few specialized centers, as more
recently developed portable lung function testing modalities are
no longer on the market (41). Initial reports from the author’s
laboratory of a simple field test of respiratory resistance using
the interrupter technique hold promise for increased use of
lung function testing in the future. While the classic esophageal
balloon/pneumotachometermethod is effective in demonstrating
increased maximal pleural pressure and allows for calculation
of pulmonary resistance and elastance as well as dynamic
compliance in severe EA, it is not sufficient for demonstrating
abnormal function in mildly affected horses in which baseline
lung function is rarely abnormal and histamine or other
bronchoprovocation or bronchodilation must be used in order
in order to detect low-grade obstruction (56). Unfortunately, in
some studies, even histamine bronchoprovocation has not been
sufficient to distinguish between normal horses and horses with
mild asthma (52), and a lack of concordance between histamine
bronchoprovocation and bronchoalveolar lavage (BAL) cytology
has been noted in several studies (57, 58). While lung function
testing and histamine bronchoprovocation have shownmoderate
to strong correlations with BAL cytology in some studies (56, 59,
60), others have not (57, 58). Methods of performing histamine
bronchoprovocation are equally important: studies in human
asthmatics have shown that it is the total dose of histamine
that is most important rather than the duration of exposure. A
more precise method of dosing may be important to establish.
In human athletes, indirect stimuli, such as cold air, hypertonic
solutions such as mannitol, exercise, and AMP are all considered
more accurate and useful in predicting asthma than are direct
stimuli such as methacholine or histamine; this is an area that
requires exploration in equine pulmonology.While hay challenge
is useful for research in severe EA, it is inappropriate in a
clinical case, especially in a horse that is expected to do athletic
work (3). In moderate to severe EA, variability in airflow should
be demonstrated not through bronchoprovocation but through
bronchodilation using either systemic (BuscopanTM) or inhaled
(albuterol, ipratropium bromide) drugs to assess reversibility; it
is possible that a 24 h period of bronchodilation is necessary for
maximum effect in horses with diaphragmatic fatigue (61).
Proposed minimum database for both practitioners in the field
and for research: In research, lung function should be assessed and
airflow variability/changes in airway caliber should be assessed
with either bronchoprovocation or bronchodilation. More research
is necessary to determine if field assessment of lung function after
bronchoprovocation or bronchodilation is sufficient to determine
change with the 23-point scoring system. It is essential that a robust,
easily used system for testing lung function in the field be developed.
Airway Secretions—Bronchoalveolar
Lavage
Unlike in human pulmonology, examination of airway secretions
is a primary method of diagnosis in EA, be it mild, moderate
or severe. Although a standard volume of between 250 and
500ml of saline using a 2m long endoscope or 3m BAL
tube is recommended (3), this practice is not always followed,
and cytology should be assessed keeping in mind that the
amount of fluid infused will affect the cell percentages. The
relationship between BAL cytology and performance is still
not clear. Certainly, poor performance has been associated
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with what have been determined to be abnormal cell types or
percentages (3). There has been much discussion as to what is
normal on BAL cytology; it likely depends on a combination
of technique, environment and population. Even the “stringent”
definition proposed by Couëtil et al. (3) of <5% neutrophils,
2% mast cells, 1% eosinophils, would be considered elevated
in some high-performance populations (62, 63). Although an
earlier study found no evidence of a clear phenotype in mast
cell vs. neutrophilic inflammation with respect to pulmonary
gas exchange during exercise (64), recently, an increase in
BAL mast cells or neutrophils was shown to negatively affect
performance (44). The way that cells are counted in BAL cytology
is also important, especially for rare cells. In our laboratory we
count a minimum of 500 cells at 400x for common cells such
as macrophages and lymphocytes or neutrophils in mild EA,
whereas for rare cells such as mast cells we count 1,000 cells.
Other techniques, such as using a 5-field differential for mast
cells, are only useful if the cell density is high (65).
The conundrum of whether to assess airway fluid from both
lungs rather than blind sampling, or to pool samples, has also
occupied attention from researchers. One group found that,
depending on whether the “loose” or “stringent” categorization
was used, 8–37% of horses would have been categorized as
control vs. mild-moderate EA if only one lung were used
(66). As it is the rare practitioner who has a bronchoscope in
the field, it is unlikely that even pooled samples (63), which
may be a better representation of overall lung inflammation,
will be taken other than in referral centers or practices. The
problem is most important for rare cells. More attention will
need to be paid in future to morphology and perhaps typing of
cells. The existence of neutrophil extracellular traps (NETosis)
in horses with severe EA presents an additional method to
determine response to treatment (67), and recently the presence
of degenerate neutrophils has been shown to raise suspicion for
bacterial infection (68). The question of macrophagemorphology
as an indicator of inflammation is also an area that will
profit from further investigation (69). Recently, as well, the
paucigranulocytic phenotype has been described in which horses
with clear signs of severe EA have low neutrophil percentages in
the BAL (46). This is thought to be due to mucus plugging of
small airways that essentially sequesters neutrophils. Although
a recent publication showed a rather shocking 81% of high-
performing European horses with mild-moderate EA had fungal
elements in the BAL (62), this remains to be confirmed in
other populations.
Proposed minimum database for both practitioners in the field
and for research: For the BAL, at least 250-mls of saline should
be used, and there is a preference for counting at least 500 cells
to adequately represent rarer cells. For research purposes where
rare cells are of interest (e.g., mast cells or eosinophils), sampling
of both lungs appears preferable. Better categorization of cells
through morphological descriptions including apparent neutrophil
extracellular traps and notations of fungal or birefringent elements
should be done. Characterization of mucus on cytology may help
to elucidate the paucigranulocytic phenotype. BAL in the field will
usually be done blindly with a specialty tube.
Airway Secretions—Tracheal Wash (TW)
The debate continues to swirl around the utility of tracheal wash
vs. bronchoalveolar lavage, with Malikides et al. (70) finding
a 37% disagreement in young racehorses, while Derksen et al.
(71) determining that there was no correlation between BAL
and TW, and others finding no relationship between tracheal
neutrophil counts and racing performance (72); thus, tracheal
cytology has been considered inappropriate for diagnosis of mild
EA (3). Recently, however, a comparison of TW and BAL in
145 horses, along with evidence of mucus and endoscopy, found
that only 17.5% of horses would have been classified differently
if they had had the other procedure, eventually concluding that
there is no gold standard—except for mast cells, which are rare
in the trachea, and thus, to be found, demand that a BAL be
performed (73).
Proposed minimum database for both practitioners in the field
and for research: Tracheal wash may be most practical for some
practitioners in the field and has the added benefit of allowing
for bacterial culture. The inability to assess mast cells adequately
continues to limit this modality. In research settings, both tracheal
aspirate and BAL are preferable.
Endoscopy
Many clinical diagnoses are made on the basis of endoscopic
visualization of mucus, with strong support from the finding that
tracheal mucus quite nicely correlated with racing performance
or lack thereof (72). The recent consensus statement considers
that the demonstration through tracheobronchial endoscopy of
mucus grade 2/5 in racehorses or 3/5 for sport/pleasure horses
is sufficient to diagnose mild-moderate EA and in support of
this recommendation, Rossi et al. (73) found that visible mucus
in the trachea is indeed likely to predict inflammation. There
are varying degrees of certainty about mucus in the trachea
predicting inflammation (49, 62, 74, 75). Nonetheless, other
studies have shown that mucus is insufficient to parse out mild
vs. unaffected cases (76). Endoscopy has also been shown to be
useful in detecting an increase in upper airway abnormalities in
horses with mild-moderate EA, with Courouce-Malblanc et al.
(77) raising the chicken-and-egg question of the relationship
between mild-moderate EA and dorsal displacement of the soft
palate, andmore recently,Wysocka andKlucinski (78) found that
more horses with mild-moderate EA had dynamic pharyngeal
abnormalities. It may be that the answer will rest in whether any
of these modalities can help to define a phenotype rather than
simply further describing an already understood phenotype.
Proposed minimum database for both practitioners in the field
and for research: Upper airway endoscopy should be performed to
rule out upper airway cause of obstruction as a primary cause of
signs or that might confound lung function testing. Assessment of
tracheal mucus should be performed.
Bronchial Biopsies/Brushings
Endobronchial biopsies offer an excellent method of sampling
larger airways, although deeper layers cannot be accessed. The
brass ring—being able to distinguish normal from remission or
mild EA—remains elusive, however, as correlates were evident
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between histopathology and impulse oscillometry and showed a
difference between horses in remission at pasture and those that
remained stabled and treated with glucocorticoids, but did not
show any difference between horses with severe EA in remission
and controls (79).
Proposed minimum database for both practitioners in the field
and for research: At this time, brushings/biopsies are not considered
part of a minimum database.
Radiography/Ultrasound
Imaging is considered an important ancillary diagnostic in
humans, but radiographs have not been shown to be sensitive or
specific in horses with EA (80). Chest CT is currently not feasible
in large animals. While endobronchial ultrasound shows promise
for the elucidation of airway smooth muscle thickening in severe
EA, the ultimate goal of being able to detect low-grade disease in
erstwhile healthy horses, or to distinguish normal from severe EA
in remission remains elusive (79).
Proposed minimum database for both practitioners in the field
and for research: at this time, imaging is not considered part of the
minimum database.
HEALTH EFFECTS OF EQUINE
ASTHMA—LAURENT COUETIL
Equine asthma encompasses mild to severe forms of chronic
airway inflammation. Severe EA affects ∼14–17% of horses in
countries with Northern, cool climate (47, 81). Mild-moderate
EA affects 68–77% of pleasure horses based on tracheal wash
cytology (neutrophils > 20%) and up to 80% of racehorses based
on BAL cytology (44, 75).
Severe Equine Asthma
Horses affected with severe EA experience exacerbation of
clinical signs when exposed to organic dust originating from hay
and bedding, in particular molds present in poor quality hay. As
a result, clinical signs tend to be worse during the winter when
horses are housed indoors for extended periods of time (82).
Some horses exhibit disease flare-ups while at pasture during
summer months (EPA) (25). These horses improve clinically
during winter or after being housed indoor. A small percentage
of horses appear to suffer from both classic severe EA and EPA.
Horses with severe asthma tend to be mature (>7 years) to old
animals and a genetic predisposition has been identified in some
families (83, 84).
The main clinical sign characteristic of severe EA is
increased respiratory effort (“dyspnea”) that can rapidly improve
following bronchodilator administration. Although the decrease
in respiratory effort following bronchodilator administration can
be detected within minutes of drug administration using lung
function testing, clinical improvement may not be apparent to
clinicians (85). Acute exacerbation is associated with increased
pulmonary artery and right-heart vascular pressures as well as
increased pulmonary artery diameter on ultrasound (86). Blood
pressure return to baseline during clinical remission however,
cardiac ultrasound abnormalities such as right ventricular wall
thickness remained increased (86). Surprisingly, severe EA is
rarely fatal unless complications develop such as cor pulmonale
(87). Affected horses are more likely to be euthanized because
owners get discouraged with the expense associated with chronic
therapy and maintaining a low-dust environment (83).
Coughing and nasal discharge are non-specific signs of
respiratory disease commonly reported in horse with severe
EA (47). Horses with a history of both coughing and mucoid
nasal discharge are at increased risk of developing severe EA
(88). Thoracic auscultation may reveal increased breath sounds
bilaterally, extended area of auscultation, and abnormal breath
sounds (i.e., crackles, wheezes). However, the thick chest wall of
horses makes auscultation an insensitive indicator of pulmonary
disease, with abnormal findings obtained in <50% of horses with
severe EA (88).
Strict management changes or medical therapy will results
in rapid improvement in clinical signs however, if exposure to
triggering factors is not addressed improvement will be short
lived or incomplete (3, 15).
Mild/Moderate Equine Asthma
This form of mild respiratory disease is mainly subclinical with
horses showing non-specific signs such as intermittent coughing
and poor performance (3). However, mild asthma should not
be ruled out in horses that do not cough because coughing is
reported in only 38% of horses with mild asthma (89). Coughing
is associated with increased BAL neutrophils (56).
Poor performance and reduced willingness to perform are
associated with increased tracheal mucus scores in racehorses
and show-horses, respectively (72, 90). In racehorses, poor
performance has been associated with increased neutrophils and
mast cells in BAL fluid (44).
There is an association between nasal discharge and increased
tracheal mucus in racehorses (49). However, the association
between tracheal mucus and BAL cytology has not been
reported yet.
TISSUE REMODELING IN EQUINE
ASTHMA AND FUNCTIONAL
CONSEQUENCES—MICHELA BULLONE
The term “remodeling” defines a process resulting in a tissue
that is structurally and architecturally altered compared to
its healthy counterpart. In asthma, structural alterations are
represented by quantitative or qualitative changes of the
bronchial wall components or their surrounding tissues, whilst
architectural alterations refer to the skewed relationships among
such structures.
Airway remodeling has been studied only in horses affected
by severe EA. An increased expression of metalloproteinases and
their tissue inhibitors has been recently reported in a group of
horses with mild respiratory signs and BAL cytology compatible
with mild EA (91). However, the possibility that the horses
studied were horses with severe EA in remission of the disease
was not excluded.
Almost all airway components undergo remodeling in severe
EA, both in peripheral (diameter < 2mm) and central airways.
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The airway smooth muscle mass as well as collagen and elastic
fiber deposition are increased in the lamina propria of peripheral
airways during severe EA remission compared to healthy airways
(92, 93). Mucostasis, mucus cell hyperplasia, peribronchiolar
metaplasia, and interstitial fibrosis are more frequently detected
in horses with severe EA in remission compared to controls (94).
However, histomorphometric techniques revealed no differences
in the number of mucus cells per mm of lamina reticularis or
in the volume of stored mucosubstance in bronchial epithelial
cells (95). Central airway remodeling during disease remission
is less pronounced compared to what is observed peripherally.
Whether airway submucosal structures are significantly altered
during severe EA remission compared to control remain to be
established (79, 96, 97).
Functionally, severe EA remission is associated with a normal
lung function in spite of significant structural alterations of
the airways. In these conditions, the respiratory resistance
correlates with the amount of collagen within the lamina
propria of peripheral airways (93), indicating that, in the
absence of bronchospasm, peripheral airway stiffness is the
major determinant of respiratory resistance in asthmatic horses.
The functional implications of peripheral remodeling become
more important during disease exacerbations, when most of the
changes are further accentuated and the mechanics of breathing
are altered (73, 94).
There is no doubt that the major determinant of airway
obstruction during severe EA exacerbations is smooth muscle
contraction and that central airways play a major role (98).
By definition, the force produced by a muscle is proportional
to its cross-sectional area. Given the increased smooth muscle
mass (and cross-sectional area) during severe EA exacerbations
(79), asthmatic muscle is “stronger” and able to contract the
thickened lamina propria observed in severe EA, further reducing
the airway lumen. Increased mucus secretions into the airway
lumen also contribute to airway occlusion (99). These same
mechanisms operate in peripheral airways, where the effects
on lung function are somewhat blunted by the fact that their
overall contribution to pulmonary resistance is low, due to
their large cumulative cross-sectional area (100). At this level,
the more relevant functional effects of remodeling are the loss
of lung elasticity and airway-parenchymal tethering. Adequate
small airway patency is guaranteed by their intimal connection
to the lung parenchyma by elastic and connective fibers. When
the lung inflates during inspiration, small airways are stretched
and passively dilate. Remodeling of elastic fibers and of the
extracellular matrix within and around the airways and in the
alveolar septa alters this mechanism, preventing the smallest
airways from remaining open (101). The effect is even worse
during expiration, when the lungs physiologically recoil and the
airway diameter physiologically narrows. With a significantly
impaired expiratory airflow, part of the air that reaches the
alveoli remains trapped. This leads horses with severe EA in
exacerbation to breath at increasing lung volumes [functional
residual capacity (102)] in the attempt to maintain airway
patency, which causes lung hyperinflation and enlarged fields of
thoracic auscultation (103).
BRITISH RACING VETERINARIANS’ VIEWS




Anecdotal evidence to date has suggested that, although
BAL sampling is widely accepted elsewhere as the diagnostic
tool of choice for cytological assessment of equine lower
airways, tracheal endoscopy and tracheal wash-based diagnostics
have remained the mainstay of routine clinical lower airway
investigations in British Thoroughbred racehorses in training.
Given the emphasis on BAL in research, this would present a
considerable challenge to furthering evidence-based respiratory
medicine in this important equine population. In a recent study
we investigated British racing veterinarians’ rationales for current
practices, and the challenges they face in relation to diagnosing
and managing racehorse airway inflammation (104).
Qualitative data were gathered through semi-structured
focus group discussions designed to capture current practices
and opinions relating to the diagnosis and treatment of
lower airway inflammation, as well as familiarity with and
views on the most recent ACVIM consensus statement
(3), in which the term “mild-moderate equine asthma” was
recommended. Four British veterinary practices, two primarily
serving the flat racing community and two primarily serving
the National Hunt (jump racing) community, in different
geographical regions of England, were purposively selected
to participate. Focus group discussions were conducted at
the practice premises, moderated by one of the authors
(TK), an experienced qualitative researcher who is not a
veterinarian. Discussions were audio-recorded and transcribed
verbatim, and transcripts were analyzed using an inductive,
thematic analysis.
In total, 25 participants contributed to the focus group
discussions (number per group ranged from 3 to11). All were
veterinarians (experience ranging from recent graduate to senior
partner), with the exception of one laboratory team member and
one veterinary student, and five were women. Discussions lasted
between 46 and 74 min.
Three key themes were developed through analysis of focus
group data: (i) An over-arching theme of serving the racing
industry within which two further themes (ii) disregarding of the
consensus and (iii) the pragmatic clinician were nested.
(i) Serving the racing industry: This was a key driver of clinical
approaches to racehorse respiratory health, which were
strongly trainer-influenced in particular. The trainer selects
horses for endoscopic respiratory assessment, often because
of training and racing schedules rather than any clinical
signs, and the approach to investigation and treatment is
strongly influenced by trainer expectations. This varies with
trainer personality, experience and trainingmethods, as well
as stage of the racing season, signalment of the affected
animal and general health on the yard, and is in turn driven
by commercial pressures of the racing industry.
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(ii) Disregard of the consensus: The unanimous view across
all four groups was that the condition defined as mild-
moderate EA by current concensus (3) is largely not seen in
British racehorses which, in the participants’ considerable
collective experience, are affected predominantly with
excess endoscopically-visible tracheal mucus largely
attributed to bacterial infections. It was also considered
unfeasible to fulfill two key aspects of the consensus case
definition: waiting for chronicity of clinical signs (>3 weeks
duration), and performing BAL sampling. Neither of these
would be acceptable to trainers, according to participants,
and participants themselves were not convinced of the
extra value of BAL sampling. The consensus statement was
therefore seen as having been developed for outsiders, by
outsiders without sufficient understanding of culture and
practices on British racing yards.
(iii) The pragmatic clinician: Participants shared a strong
professional identity as pragmatic clinicians often required
to base clinical decision-making on direct personal or
collective experience, rather than on research-based
or laboratory evidence. Cytological examinations of
tracheal wash samples were defended as valuable when
interpreted sequentially and combined with knowledge
of the history and idiosyncracies of the individual horse
and yard. Although this approach was generally viewed
positively as flexible and individualized, participants
did also express some frustration with the sometimes
unsatisfactory jigsaw of diagnostic information available
to them, particularly in relation to discrepancies between
clinical and laboratory findings.
Our work has highlighted a lack of alignment between clinical
practice on British racing yards and international consensus
on diagnosing lower airway inflammation, which constitutes
a barrier to furthering development of a contextually-relevant
evidence-base for this population. Equine clinicians elsewhere
may find themselves in disagreement with some of the opinions
expressed, or practices described, by our study participants.
However, these investigations were designed to understand the
experiences and rationales of clinicians in the specific context
of British racing practice. The strength and consistency of views
expressed support the anecdotal evidence that, in this context,
tracheal endoscopy and wash sampling are widely regarded
as the best available means of providing the non-invasive
monitoring of respiratory health expected by trainers and used
to inform training- and racing-related decisions. It would be
interesting to determine whether similar approaches are being
taken elsewhere, particularly in populations of yearling and 2 year
old Thoroughbred racehorses in training. Given the considerable
resistance to BAL sampling in British racing, development of
new tracheal-based or other minimally-invasive diagnostics,
including appropriate biomarkers and suitably sensitive, portable
lung function tests, would be valuable. Furthermore, our
participants’ views that mild-moderate EA as defined by current
consensus is largely not seen in British racehorses suggest
that research furthering our understanding of the etiology and
pathogenesis of airway inflammation in this equine population is
still required.
THE MICROBIOME IN EQUINE
ASTHMA—RENAUD LEGUILLETTE
The respiratory system is an interface between the outer
environment and the inner body. Lower airways have historically
been seen as a sterile milieu, thanks to the anatomical
configuration, local surface immunity and mucus production
and clearance systems (105). However, with the development
of high sensitivity and high throughput technologies, the
microbiota of the respiratory system has been described in
healthy subjects in many species, including horses (106, 107).
Further investigation of the relationship between infectious
agents, lower respiratory tract microbiota and the development
of mild EA is warranted.We and others have reported descriptive
results about the microbiota of horses with mild EA (107, 108),
but the causality between bacterial flora and the disease is far
from being understood.
Studies on the microbiome use DNA extraction followed
by high throughput amplification and sequencing of the 16S
amplicon (109). The sequences are then filtered and aligned
against a taxonomy database to identify and organize operational
taxonomic units (OTUs). Descriptive analysis of the phyla, OTUs
and bacterial species are then performed, followed by statistical
analysis at the community level (within and between samples;
alpha and beta diversity, respectively) and at the individual
level (OTU diversity analysis). Statistical analysis can be used
to compare between groups: healthy horses vs. those with mild
asthma, upper vs. lower respiratory tract (109).
The lower airways have a decreased richness (alpha diversity,
corresponding to the number and proportion of each bacterial
species) when compared to the upper airways in healthy horses
(107). However, a very large majority of the same OTUs are
present in both the upper and the lower airways, showing
an overlap and some continuity in the bacterial population
between the two anatomical environments in healthy horses.
Furthermore, treatment with corticosteroids did not affect the
composition of the bacterial flora in the upper airways (107). The
role of the upper airways microbiota in mild EA is unknown,
but two studies did not find any difference in beta diversity of
the upper airways between healthy horses and those with mild
EA (107, 108).
The relationship between bacteria and the lower respiratory
tract of the equine host seems to be dynamic. As an example,
a change in the environmental respirable particulates has an
effect on the lower respiratory tract flora in horses. Furthermore,
treatment with systemic or nebulized dexamethasone induces
some changes in the microbiota of the lower respiratory
tract in both healthy and mild asthma horses (107). Systemic
dexamethasone administration decreased the evenness of the
flora and increased the abundance of 9 OTUs. There is an
agreement between studies that the lower airways microbiota
between healthy and mild EA horses are clearly different (107,
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108). Interestingly, Streptococcus is one of the 6 OTUs which
differed with disease status, and was the OTU with the greatest
increase in relative abundance in mild EA.
The effect of the environment on the composition of the
lower airways’ microbiota is also a common finding between
studies (107, 108). However, a study found that treatment
with corticosteroids had more effect on the composition of the
bacterial flora than changes in the environment (107).
The microbiome studies are recent in equine medicine and
are limited to being descriptive. The challenge for the scientific
community will be to answer the causality dilemma of the
chicken or the egg regarding the role of the airway microbiota
in mild EA.
ROLE OF VIRUSES IN EQUINE
ASTHMA—NICOLA PUSTERLA
Human Asthma
Asthma development in humans is most probably caused
by the interaction of multiple factors, including genetics,
allergen exposure, microbiome and invading pathogens.
Human rhinovirus, human respiratory syncytial virus, human
metapneumovirus, human parainfluenza virus, human
enterovirus and human coronavirus are strongly associated
with asthma exacerbations (110). The association between
human rhinovirus-induced wheezing and the development of
childhood asthma/wheezing has been confirmed in a recent
meta-analysis (111). The risk for asthma by age 6 years has been
shown to increase (odds ratio 9.8) if children have been wheezing
with rhinovirus during the first 3 years of life (112). Further,
many prospective long-term follow-up studies have shown
that human respiratory syncytial virus-induced bronchiolitis is
associated with later development of asthma (113). However,
the pathogenic role of respiratory viruses as triggers for the
development and/or exacerbation in asthmatic human patients
has not been fully characterized. Changes in the immune
response to viral infections in genetically predisposed individuals
are very likely to be the main factor involved in the association
between viral infection and asthma (114).
Equine Asthma
The pathogenesis of EA remains incompletely defined. However,
similar to human asthma, a multifactorial process is suspected.
Conditions associated with exercise, feeding and housing
practices, location, seasonality, infection of the upper and lower
airways and genetic influences have been linked to EA (7, 8,
115, 116). A variety of viral [equine influenza virus (EIV),
equine herpesviruses (EHV) equine rhinitis viruses (ERVs)]
and bacterial (Streptococcus equi subspecies zooepidemicus,
Actinobacillus spp., Pasteurella spp.) etiological agents have been
linked to mild to moderate EA (49, 117). It remains to be
determined if these agents are triggers for the development of EA
or are secondary colonizers of already compromised airways.
Evidence for Viruses in Equine Asthma
Viral respiratory infections are one of the most common health
problems in horses throughout the world (Table 1). These
infections are often self-limiting and a full recovery can be
expected in most horses. Young performance horses, such
as racing horses, have an increased risk of respiratory viral
infections. This relates to age susceptibility, commingling, stress
and suboptimal biosecurity protocols (119, 122, 123).
Amongst respiratory viruses, only EIV and ERVs have
an affinity to the lower respiratory tract, leading to airway
hyperresponsiveness. Clinical signs associated with EIV are
usually more severe than those seen with mild to moderate
EA. Further, no association has been determined between mild
to moderate EA and infections with EIV, EHV-1 and EHV-4
(118, 120, 121). This is in sharp contrast to the detection of ERVs
(ERAV and ERBV), known to cause subclinical or mild clinical
disease (118, 120, 121). In a recent study, horses with mild to
moderate EA were significantly more likely to have a positive
titer as well as higher log-transformed titers to ERAV when
compared to control horses (120). In another study, the detection
of ERBV by qPCR was significantly associated with coughing in
Standardbred racehorses in training (118). Subclinical respiratory
viral activity in horses with poor performance has been associated
with EHV-2 and EHV-5 infection (118, 120). In a recent
study, the detection of EHV-2 by qPCR in nasal secretions
was significantly associated with mild to moderate EA (120).
In another study, the detection of EHV-2 by qPCR was
significantly associated with coughing and excessive tracheal
mucus in Standardbred racing horses (118). These results are in
sharp contrast to two recent studies performed on 66 Swedish
Standardbred trotters, which were followed for 13 months via
qPCR analysis of nasal secretions and serology (121, 124). Despite
occurrence of poor performance and subclinical viral activity in
the Swedish Standardbred trotters, the authors were unable to
detect associations between EHV-2/-5 and clinical respiratory
disease and/or poor performance. These conflicting results reflect
the ongoing challenges in establishing causality between mild to
moderate EA and gamma herpesviruses, known to be ubiquitous
in both healthy and clinically affected horses.
In conclusion, associations between specific viruses detected
via antigen or antibody detection and clinical signs of mild
to moderate EA may suggest that viruses may play a role
in triggering or exacerbating asthma. However, because
some viruses are ubiquitous both in healthy and clinically
affected horses or are often associated with subclinical
disease, establishing causality is challenging and in need for
further research.
ROLE OF NON-INFECTIOUS EXPOSURES
IN EQUINE ASTHMA—KATY IVESTER
A growing body of research demonstrates the link between
organic dust exposure and EA. Introduction of horses to
high dust environments not only induces profound BAL
fluid neutrophilia and airway obstruction in horses susceptible
to severe asthma, but also significant neutrophilic airway
inflammation in previously healthy horses (125, 126). Outside
of the experimental exposure setting, higher dust exposure has
also been associated with increased risk of tracheal mucus
accumulation in racing Thoroughbreds (127).
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TABLE 1 | Association of respiratory viruses with mild to moderate equine asthma based on antigen and/or antibody detection.
Virus Year Country Population Sample type Outcome References
EAV 2015 Sweden Standardbred trotters Nasal secretions No detection by qPCR (118)
EIV 2015 Sweden Standardbred trotters Nasal secretions No detection by qPCR (118)
2015 USA Adult horses BAL fluid No detection by qPCR (119)
2016 France Standardbred trotters Nasal secretions TW No detection by qPCR (120)
ERAV 2015 Sweden Standardbred trotters Nasal secretions No association with poor performance (118)
2015 USA Adult horses BAL fluid High seroprevalence titers (119)
2016 France Standardbred trotters Nasal secretions No detection by qPCR (120)
TW No association with equine asthma
ERBV 2015 Sweden Standardbred trotters Nasal secretions No association with poor performance (118)
2015 USA Adult horses BAL fluid No association with equine asthma (119)
2016 France Standardbred trotters Nasal secretions No association with equine asthma (120)
Tracheal wash Detection by qPCR in horses with cough
EHV-1/-4 2015 Sweden Standardbred trotters Nasal secretions No association with poor performance (118)
2015 USA Adult horses BAL fluid No detection by qPCR (119)
2016 French Standardbred trotters Nasal secretions TW No association with equine asthma (120)
EHV-2 2015 Sweden Standardbred trotters Nasal secretions No association with poor performance (121)
2015 USA Adult horses Nasal secretions Detection associated with equine asthma (119)
2016 France Standardbred trotters Nasal secretions No association with equine asthma (120)
Tracheal wash Detection by qPCR in horses with cough excessive tracheal mucus
EHV-5 2015 Sweden Standardbred trotters Nasal secretions No association with poor performance (121)
2015 USA Adult horses BAL fluid No association with equine asthma (119)
2016 France Standardbred trotters Nasal secretions TW No association with equine asthma (120)
ECoV 2016 France Standardbred trotters Nasal secretions TW No detection by qPCR (120)
EAdV-1 2016 France Standardbred trotters Nasal secretions TW No association with equine asthma (120)
EAdV-2 2016 France Standardbred trotters Nasal secretions TW No detection by qPCR (120)
BAL, bronchoalveolar lavage; EAV, equine arteritis virus; EAdV, equine adenovirus; NS, nasal secretions; PP, poor performance; STBD, Standardbred; TW, tracheal wash.
Barn dust is a complex mixture, rich in potential sources
of allergens as well as immunomodulators such as endotoxin
and β-glucan (128, 129). In addition to individual horse factors
such as age and susceptibility, this complexity may partially
account for the heterogeneity of asthma phenotypes. Respirable
particulates, nominally <4µm in diameter, have been linked
to eosinophilic inflammation in young Thoroughbreds entering
race training (130) and neutrophilic inflammation in actively
racing Thoroughbreds (44). Increasing respirable endotoxin
exposures have been shown to provide an apparent protective
effect against neutrophilic inflammation at low doses (44), while
high doses of endotoxin augment the inflammatory response to
particulates (131), suggesting a non-linear response to inhaled
endotoxin in the horse. Mast cell inflammation has been
found to be common in both young, untrained Thoroughbreds
(130) and those that are actively racing (44), but unrelated
to respirable dust or respirable endotoxin exposures. Instead,
BAL mast cell proportions are related with respirable β-glucan
exposures. Conversely, inhalable dust exposures have not been
found to affect BAL inflammatory cell proportions. Thus,
inhalable particulates, those nominally <100µm in diameter,
appear to be less relevant than respirable particulates in equine
respiratory health.
Setting exposure recommendations will require better
understanding of the dose-response to inhaled non-infectious
agents across wider ranges of age, breed, and discipline through
study designs that include both exposure and respiratory
health outcome measures and utilize appropriate statistical
tools to relate them. Advanced characterization of respiratory
health, such as investigation of alveolar macrophage function
and BAL fluid cytokine profiles, coupled with extensive
exposure assessment is likely to offer valuable insight into EA
pathophysiology and identify new targets for intervention.
Miniaturization of optical particle counters has rendered real-
time breathing zone exposure measurements on the horse both
affordable and technically feasible. Finally, the equine airway
is arguably most susceptible to particle penetration during
athletic exertion due to large tidal volumes and extension of
the head and neck, yet the exposures that horses sustain during
exercise are largely unexplored. Such measures of exposure are
complicated by the air speed and turbulence generated at the
breathing zone during such activity and will require specialized
sampling strategies.
THE ROLE OF NEUTROPHILS IN EQUINE
ASTHMA—GABRIEL MORAN
Neutrophils are key actors in host defense, migrating toward
sites of inflammation and infection, where they act as
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early responder cells toward external insults (132). However,
neutrophils can also mediate tissue damage in various non-
infectious inflammatory processes. Airway inflammation is one
of the primary characteristics of an asthma-affected horse’s
response to aeroallergens with neutrophilic bronchiolitis being
the main lesion (133). The mechanism by which airway
inflammation develops in EA is a multifaceted and dynamic
process. Current knowledge suggests that the inflammatory
component of this disease results from a combination of both
the innate and adaptive immune responses (134). Generally,
airway inflammation involves activation of pathogen-specific
inflammatory cells, modulation of gene transcription factors, and
release of inflammatory mediators (135). Within the airways,
neutrophils likely contribute to bronchoconstriction, mucus
hypersecretion, and pulmonary remodeling by release of pro-
inflammatory mediators, including the cytokines interleukins
8 and 17, neutrophil elastase, reactive oxygen species, and
neutrophil extracellular traps (NETs) (118–121). Oxidative stress
in horses with asthma is evidenced by the increase in elastase and
decrease in ascorbic acid concentrations in BALF associated with
neutrophilia secondary to exposure to organic dust (136). The
pathogenic role of NETs has been described for many infectious
and non-infectious human diseases, including respiratory cases
with a massive influx of neutrophils into the airways (137).
Excessive NET release is particularly deleterious in lung diseases
because NETs can expand easily in the pulmonary alveolar space
and cause lung injury. Furthermore, NETs and their associated
molecules can directly induce epithelial and endothelial cell
death (138).
The mechanisms that regulate neutrophil functions in tissues
are complex and incompletely understood and must be regulated
with exquisite precision and timing. Timely apoptosis of
neutrophils is central to the resolution of inflammation; dying
neutrophils are known to stimulate their own efferocytosis,
inducing macrophagic transition from a pro-inflammatory to
an anti-inflammatory profile (139). Thus, dysregulated apoptosis
and mechanisms of inflammation may play an important role
in the pathogenesis of EA. The persistence of apoptosis-resistant
neutrophils in the airways of horses with asthmamay also impede
timely neutrophil clearance and delay the resolution of airway
inflammation. The discovery and development of compounds
that can help regulate ROS, NET formation, cytokine release and
clearance of airway neutrophils would be highly beneficial in the
design of therapies for EA (133).




Asthma is a highly heterogeneous condition of the lung. Akin to
the lining of the gastrointestinal tract, the lining of the airways
is also in contact with external substances throughout life.
Ingested substances generally pass through the gastrointestinal
tract unidirectionally, and a careful balance between processing
of digested food materials, nutrient absorption and limiting
immunoreactivity is maintained during homeostasis, with well-
known severe consequences of deviations in this balance. The
airways function differently in that only gaseous substances
normally pass into the distal alveoli and are exhaled in the
reverse direction. Inhaled particulates also have to be expelled in
reverse direction toward the nasopharynx by largely mechanical
means or taken up by alveolar macrophages for disposition with
minimal inflammatory evocation (140). Hence, a complex and
selective epithelial barrier with differing functions characterizes
both organs.
The epithelium lining the airways has unique composition,
morphology and function throughout the lung, and is intimately
connected to subepithelial structures such as the basement
membrane, mucous glands, smooth muscle, fibroblasts,
endothelium and immune cells. The epithelium forms a barrier
between inhaled components and the subepithelial constituents,
and also has to balance efficient transfer of gases with controlled
reactivity to non-gaseous components. While the lesions of
severe EA manifest predominantly with inflammation, smooth
muscle hyperplasia and fibrosis of the peripheral airways and
surrounding tissues, the larger airways are exposed to the same
inhaled substances and also have morphological, functional and
molecular changes (141).
Research initially focused on the role of club cell secretory
protein (CCSP), a member of the secretoglobin family produced
by non-ciliated epithelial cells concentrated within the
epithelium at the transition from bronchi to bronchioles.
Club cells are recognized as epithelial progenitor cells that
can differentiate into ciliated and other specialized cells of the
airway epithelium, participate in reduction of reactive oxygen
toxicants through cytochrome enzymes, and their hydrophobic
secreted protein inactivates a range of inflammatory mediators.
Horses with severe asthma have fewer club cells and lower
concentration of CCSP in airway fluids, which may be a function
of chronic inflammation resulting in reduced regenerative
capacity of the airway epithelium (142). Unique relative to
other mammals, equids have two expressed CCSP genes that
differ in 12 of 70 amino acids, and also in their interaction with
hydrophobic molecules (143). Recombinant eCCSP increased
neutrophil oxidative burst, phagocytosis and extracellular trap
formation, lending support to the notion that loss of club cells
has deleterious effects on lung health (144).
Whole transcriptomic changes in endobronchial epithelial
biopsies from sites from 5th to 12th generation bronchi were
investigated with next-generation sequencing. Each horse served
as its own control to identify changes in gene expression
associated with an inhaled challenge since inter-individual
variability exceeded changes attributable to the challenge. A
bioinformatics pipeline including quality control measures
to account for duplicates, variable sequencing depth and
dispersion was implemented, results were mapped to the
equine genome, and predicted proteins were procured with
a combination of software and manual approaches to assign
appropriate Ensemble IDs for analyzing interactions. An overall
conservative analytic approach yielded 111 genes differentially
expressed in horses with severe asthma as a result of a
challenge, with the majority up-regulated (145). Not surprisingly,
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many up-regulated genes pertained to inflammatory mediators
and effectors and were well-known members of protein
interacting networks. However, somewhat more surprisingly,
genes with altered expression also concerned more broadly
epithelial cell formation and maintenance, and the circadian
rhythm, suggesting that multiple cell properties are affected in
exacerbated EA at the transcriptomic level. Subsequent analysis
of enriched gene sets in asthmatic horses further highlighted the
importance of cell cycle regulation and repair pathways (146).
Transcriptomic studies of this nature yield a great deal of
information, which requires subsequent confirmation regarding
cell specificity, correlation with protein expression and function,
and extension to amore robust number of affected and unaffected
individuals. Albeit, there is strong evidence to indicate that the
bronchial epithelium is profoundly altered during exacerbation
of severe EA, and this insight offers new venues for investigating
the role of specific proteins and for potential therapeutic
targets (147, 148).
GENETIC RISK FACTORS OF EQUINE
ASTHMA—VINCE GERBER
The entire spectrum of EA is influenced by interactions between
the environment and genetics, but almost all research in this field
has focused on the severe clinical phenotype.
While no specific genetic risk factors have been reported for
mild to moderate forms of EA, genetic susceptibility to certain
bacterial lower airway infections could potentially be relevant
(149). Furthermore, mild but persistent respiratory signs such
as occasional coughing and nasal discharge may represent early
phenotypic indicators for an increased risk to later development
of severe EA (88). This suggests that the genetics of milder forms
of EA may be worth investigating in longitudinal studies.
Severe EA has been shown to be partly heritable in several
breeds and has been the focus of genetic research involving
family and epidemiological studies, whole-genome scans and
investigation of candidate genes. Reports of marked familial
aggregation of severe EA date back 70 years (150). Parent, age,
and stable environment have significant additive effects that
increase the risk for developing severe EA as defined by a history
of persistent frequent coughing and/or increased breathing effort
(43, 151). Offspring of affected sires have a more than 4-fold
increased risk for developing severe EA (50).
Whole genome scans in high-prevalence families indicate two
chromosome regions with a genome-wide significant association
with severe EA (152). Importantly, the associations differ
between the families: region ECA13 in one family and ECA15 in
another family. Further association and gene expression studies
indicate interleukin 4 receptor as a candidate gene in a subset
of EA-affected horses. Molecular pathway analyses of genomic
and proteomic data showed interactions between interleukin 4
receptor and SOCS5 upstream of an importantmolecular cascade
involving nuclear factor κB (153).
So far, no causal genetic variant has been identified in
interleukin 4. An allelic case-control genome-wide association
study in the general Warmblood population revealed another
region on chromosome 13. The best-associated marker was
located in the protein-coding gene TXNDC11, which may be
involved in regulating hydrogen peroxide production in the
respiratory tract epithelium as well as in the expression of
MUC5AC mucin (154). No genomic copy number variations
were found to be associated with severe EA (155). Integrative
analyses combining GWAS, differential expression (DE), and
expression quantitative trait loci (eQTLs) were not able to
uncover causative genetic variants that contribute to severe EA
through gene expression regulation. However, results showed
interesting similarities to human asthma with disease-associated
genetic variants in CLEC16A that also regulate gene expression
of DEXI (156). Furthermore, global gene expression studies
of mRNA and miRNA levels in these high-prevalence families
have shown impaired cell cycle regulation and CD4+ T
cell differentiation into Th2/Th17 cells, respectively, in severe
EA (157, 158).
At present, none of these associations are useful genetic
markers in the general population. Most of the findings pertain to
Warmbloods only, or even only to certain lines and families. The
fact that the chromosomal regions and the mode of inheritance
do not agree between families indicates genetic heterogeneity
for severe EA: depending on the genetic make-up of affected
horses, different genes confer the susceptibility for the disease.
It appears that the genetic basis of severe EA is robust, but
remarkably complex. Polygenic complexity, potentially with a
larger number of genes that each may only contribute <10% to
the total genetic effects, maymake it difficult to discover causative
variants. Nevertheless, the genetics of severe EA has revealed
interesting links between severe EA, allergic skin diseases and
susceptibility to intestinal parasites (159, 160).
ARE PERTINENT BIOMARKERS OF
EQUINE ASTHMA ALREADY AVAILABLE
TO PRACTITIONERS AND
RESEARCHERS?—ARTUR NIEDZWIEDZ
According to the National Institutes of Health, a biomarker is
a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes or
pharmacologic responses to a therapeutic intervention (161). In
practice, biomarkers include tools and technologies that can help
in understanding the prediction, cause, diagnosis, progression,
and outcome of treatment of a disease. Although BAL cytology
has been recognized as the gold standard for diagnosing
respiratory diseases such as EA, currently, sensitive and specific
biomarker tests useful in routine laboratory diagnostics are
being sought. A simple biomarker capable of distinguishing
between animals with lower airway infections and those with
non-infectious airway inflammation would be helpful. Although
the diagnosis of severe cases of EA is relatively easy, it is
difficult to diagnose cases in remission or horses with a mild
form of the disease. Ideally, molecular biomarkers should
reflect a feature of relevant pathological processes. In addition,
biomarker assessment should be easy, low-cost, technically
accurate, repeatable and have an acceptable risk. Therefore, a
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measurement from easily obtainable body fluids or tissues is
preferred, such as blood, urine, exhaled breath condensates, as
opposed to BAL, transbronchial biopsy or lung biopsy (162).
Several biomarkers are present or altered in the airways or
circulation of horses with asthma. Inflammatory markers such as
acute phase proteins and cytokines have been studied as markers
of systemic inflammation. However, the available literature on
markers of systemic inflammation in horses with severe EA is
not well-characterized and controversial (116, 163–165). Apart
from reports on differential expression of cytokines during the
course of severe EA, only a few acute phase proteins have been
investigated. Haptoglobin is a suitable marker of both acute and
chronic systemic inflammations, whereas high concentrations
of serum amyloid A indicate acute inflammation. One study
found no difference in the acute phase protein levels (serum
amyloid A, c-reactive protein, haptoglobin) between horses with
mild EA and those with other causes of exercise intolerance
(166). Another study found elevated haptoglobin concentration
in horses with mild EA (167).
Surfactant protein D is a large multimeric collagenous
glycoprotein produced mainly by type II epithelial cells in the
lungs and is also detectable in the serum. Serum surfactant
protein D has been identified as a potential systemic biomarker
for some pulmonary diseases in humans, such as idiopathic
interstitial fibrosis and acute respiratory distress syndrome.
Elevated serum levels of surfactant protein D have been detected
in horses with mild EA (167, 168).
Circulating immune complexes are proteins that result from
an immune response against an organism or antigens of various
origin. In humans, circulating immune complexes are detectable
in a variety of systemic disorders such as autoimmune diseases,
allergies and infectious diseases (169). High levels of circulating
immune complexes have been reported in horses with severe
EA (165). Another study found circulating immune complexes
useful for differentiating healthy vs. severe EA, and monitoring
corticosteroids therapy (170).
The main group of enzymes responsible for collagen and
other protein degradation in the extracellular matrix are
matrix metalloproteinases (MMPs), while tissue inhibitors of
metalloproteinases (TIMPs) lead to fibrosis formation. Collagen
is the main structural component of connective tissue and
its degradation is a very important process in development,
morphogenesis, tissue remodeling, and repair. In horses with
severe EA, MMPs, TIMPs, and their ratios are useful in the
evaluation of the severity of respiratory disease and in identifying
subclinical cases (91). Furthermore, MMP-2, MMP-9, TIMP-1,
and TIMP-2 are significantly decreased after therapy with inhaled
glucocorticoid therapy (171).
Exhaled breath condensate is a promising source of
biomarkers of lung disease in humans. Exhaled breath
condensate hydrogen peroxide concentration and pH were
higher in horses with mild EA, vs. controls (69). Additionally,
both hydrogen peroxide and pH had a positive association with
BAL neutrophil percentage, while leukotriene B-4 demonstrated
a positive association with BAL eosinophil percentage. Another
study characterized the metabolomic profile of tracheal wash
and exhaled breath condensate in healthy horses and those
with severe EA (172). Higher concentrations of histamine and
oxidant agents, such as glutamate, valine, leucine, and isoleucine,
as well as lower levels of ascorbate, methylamine, dimethylamine
and O-phosphocholine, were found in the group of severe EA,
compared to healthy controls.
Many biomarkers of EA have been studied—some are already
being used in clinical settings, while others require further
studies. However, history, clinical evaluation, and BAL still
constitute the basis for diagnosis of EA.
HOW DO WE STANDARDIZE
IMMUNOLOGIC LABORATORY
TESTING?—ERIC RICHARD
Immune response has mainly been investigated in the airways
of horses with severe EA and more recently mild-moderate EA,
while still representing one of the futures direction for research
stated in the 2016 ACVIM Consensus Statement (3). Such
characterization has mostly been performed through relative
mRNA expression of various cytokines in BAL fluid, while
several publications also reported protein concentration in BAL
fluid for few cytokines. Various methodologies for cytokine
mRNA expressions have been published (e.g., SYBR Green or
Taqman technology, design of primers and probes, relative
quantitation, etc.).
Variation in methodologies may ultimately prevent objective
comparisons between reports, as well as the implementation of
prospective, multicenter studies. Such diversity should however
not be considered as a scientific weakness, and methodological
homogenization among the various research groups neither
represents a prerequisite nor a final goal to be reached. However,
evaluation of the methodological performances of different
research laboratories might represent a relevant goal. In this
manner, implementation of inter-laboratory comparisons based
on international standards (e.g., ISO/IEC 17043 and ISO 13528)
warrants further consideration.
Let’s consider for example mRNA expression of two different
cytokines by PCR in BALF samples. As a first and informal
procedure, a simple “blind test” could be performed among up
to four different teams. In this procedure, the “reference lab” will
provide the three other labs with aliquots of the same sample(s).
Each teamwill evaluatemRNA expression for these two cytokines
based on their own procedures, and comparisons of the results
obtained and agreement among the teams can be evaluated.
This “blind test” might then be repeated on a regular basis,
systematically alternating the “reference lab” within the group. In
the end, the procedure will provide an objective evaluation of the
results diversity among the teams, but clearly will not determine
whether several teams are more efficient than others for these
specific analyses.
A second and more structured procedure would require
the specific synthesis of standards (mRNA for two different
cytokines in this case), and the development/validation of
relevant conditioning and conservation procedures. A similar
group of four different labs would first evaluate their ability
to detect and quantify predetermined amounts of analytical
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standards (evaluation of the detection, not of the sample
extraction, etc.). This step is a necessary preliminary, in the
absence of reference methods. A panel of at least 10 samples
(previously calibrated with standards) would then be tested,
including several identical ones (for repeatability) and submitted
to the group (including a “self-shipment”) for testing and further
statistical analyses (agreement, etc.). Once the methodological
performance of the lab is considered acceptable for this panel,
the procedure might then be repeated with another two cytokines
and so on. In the end, the whole panel of standardized samples
might allow the establishment of a labeling, accessible to any
voluntary laboratory involved in equine asthma.
Mandatory considerations about such comparisons are
that there is no trap, and this does not represent an
overall examination of laboratories, but simple evaluations of
procedures. All labs are expected to use their methodologies,
whether or not the technologies are similar within the group.
Among others, samples conditioning, conservation, shipment
and their associated costs will represent major issues to
be considered, and this should be more broadly associated
with virtuous initiatives such as the Equine Respiratory
Tissue Biobank.
FUTURE RESEARCH DIRECTIONS IN
EQUINE ASTHMA: SYSTEMATIC
SUMMARY OF SUGGESTIONS FROM
FINAL ROUNDTABLE
DISCUSSIONS—JACQUELINE M.
CARDWELL, MELISSA MAZAN, LAURENT
COUETIL, RENAUD LEGUILLETTE, ERIC
RICHARD
Several group discussions were conducted during the
2019 Havemeyer Equine Asthma Workshop to identify
future research priorities. Initial rotating small-group topic
explorations (pathophysiology, risk-factors, diagnostic methods
and phenotype definition) facilitated by members of the
workshop organizing team, were followed by a final large group
“roundtable” discussion of key directions for future EA research.
The discussion was informed by data gathered directly from
∼30 participants (i.e., all who attended the final roundtable),
who were invited to propose up to three short- or long-term,
focused or “big picture,” research topics or ideas that they
considered to be key future research directions. These data were
submitted anonymously, during the workshop, as free-text on
paper and loosely arranged into broad categories for further
open discussion.
Following the workshop, in order to present an accessible,
systematic and non-selective summary of the ideas proposed by
participants, the free-text data were collated in Microsoft Excel
for content analysis using an approach based on recommended
methods for quasi-qualitative data (173, 174). The text was
transcribed verbatim and coded at two levels to categorize
content into (i) broad topic areas (Level 1) and (ii) specific
subsets of these topics (Level 2). All instances of each Level 1
FIGURE 1 | Word Cloud summary of topic areas proposed by workshop
participants as key future directions for equine asthma research.
topic code were then exported into online software (WordItOut)
to create a word cloud (Figure 1), in which the relative
frequencies of occurrence of each topic are represented by
font size.
Overall, 62 responses were received, each proposing between
1 and 3 research ideas, resulting in a total of 117 research ideas,
which were organized into the 14 broad topic codes presented
in the word cloud. Some research ideas encompassed more than
one topic and were identified with multiple codes to reflect this.
Frequencies of occurrence of each code ranged from n=28 for
“diagnostics” to n= 1 for “genetics.”
Specific proposed areas of interest in the dominant
“diagnostics” category were the development of improved,
non-invasive field diagnostics through the identification of
suitable biomarkers, development of portable lung function
tests, improved understanding of relative values of tracheal wash
in comparison with BAL cytology, or relationships between
the two, and identification of gold standards for all of these
diagnostic modalities.
Another key topic was phenotype distinction (21
occurrences)—in particular to clarify any distinction between
mild and moderate EA, and to determine whether or not such
a distinction is valuable in terms of differing pathophysiology,
diagnostic indicators, therapeutics or prognosis. As with many
of these proposed topics, phenotype distinction rests on the
back of the category “diagnostics”—pointing out a self-identified
weakness on the part of EA researchers that the goal of
identifying the horse with asthma so mild that it does not present
as respiratory disease per se, continues in many cases to elude
us and underscores a collective pragmatism that there is little
benefit in understanding the fine points if we cannot definitively
identify the case in the first place.
Ideas relating to therapeutics (18 occurrences) included
investigating the efficacy of different treatments including
environmental management and any evidence for the value of
antibiotics, as well as the development of optimal nebulized
glucocorticoids, alternatives to corticosteroids, immunological
treatments, respiratory probiotics, other novel therapeutics (e.g.,
MARCKS inhibitor peptide), and individualized treatments for
different endotypes and phenotypes.
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Suggestions relating to pathophysiology (17 occurrences)
included furthering our understanding of the role of
environmental pollutants, of when a physiological response
becomes a pathological response and of factors influencing
progression from mild to severe equine asthma.
Standardization (11 occurrences) referred in particular to the
need to develop or agree on standardized diagnostic approaches,
including in relation to BAL collection techniques, laboratory
processing and cytological methods and threshold values,
context-specific reference ranges, development of a central
repository of protocols and improved quality control protocols.
A central repository of standard protocols was suggested.
Academic-clinical communication (9 occurrences) was
recognized as an area for general improvement. Related research
suggestions included improving our understanding of the views
and practices of field clinicians, as well as their perceptions
of disease progression and treatment efficacy, particularly in
regions outside the UK (to build on the Kinnison and Cardwell
UK study) (104). This would inform the enhancement of multi-
directional communication between academia, referral and first
opinion clinical practice, development of guidelines and apps for
field practice and overall improved dialogue and engagement.
Better use of collaborative, epidemiological and longitudinal
studies was suggested for many topics and included multicenter,
cross-country collaborations, more use of the existing tissue bank
and the initiation of a new Equine Asthma Group.
It is recognized that the ideas for research directions generated
through this roundtable discussion at the end of a 3 day workshop
are subject to biases and influences relating to the interests,
priorities and perceptions of workshop participants. However, by
using and describing a systematic method of representing the
ideas proposed, we have aimed at least to be transparent in our
reporting of this. Further, longer-term, international discussion
and exchange of views will be facilitated by one of the key
outcomes of this workshop, which was the development of the
new Equine Asthma Group. The aim of this group is to offer a
platform of information for veterinary practitioners and horse
owners as well as a resource for researchers to collaborate and
exchange ideas on the understanding of EA. It was suggested that
this group could lead some initiatives in line with the proposed
areas of interest described above. There are plans for this group
to develop some guidelines for the diagnosis and treatment of
equine asthma, including for example the standardization of
diagnostic methods, as mentioned above. Development of an
Equine Asthma Group website and other communication tools
are now underway as an internationally collaborative initiative.
CONCLUSION
The 2019 Havemeyer Equine Asthma Workshop has paved the
way for a better understanding of this many-faceted disease
by bringing together researchers and clinicians to identify both
the needs of the equine industry for effective treatments and
at the same time focus researchers on the gaps in knowledge
and understanding that will facilitate our ability to deliver
on these needs. The participants made clear the requirement
for more accessible, standardized diagnostics that will enable
us to understand the underlying pathophysiology and identify
specific phenotypes and endotypes and thus create more
targeted treatments or management strategies. By creating an
Equine Asthma Group, we will have a platform to unify the
veterinary practice and research communities through agreed-
upon research targets and through published and easily accessible
guidelines, creating a point of convergence for identification of
cases that will facilitate research.
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